Class C CpG oligodeoxynucleotides as a single agent and in combination with radiotherapy efficiently delayed growth of subcutaneous B16F1 tumors

Innate Immunity

Volumn 15, Issue 5, 2009, Pages 313-321

  Cerkovnik, Petra ^a   Jezersek Novakovic, Barbara ^a   Stegel, Vida ^a   Novakovic, Srdjan ^a  

^a INSTITUTE OF ONCOLOGY   (Slovenia)

Author keywords

CpG ODN; Dendritic cells; Innate immunity; Radiotherapy; Tumor vaccine

Indexed keywords

B LYMPHOCYTE ANTIGEN; CD86 ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; CPG OLIGODEOXYNUCLEOTIDES CLASS C; DENDRITIC CELL VACCINE; T LYMPHOCYTE ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGENICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL MATURATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CROSS PRESENTATION; DENDRITIC CELL; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MEGADOSE; FEMALE; MELANOMA B16; MELANOMA CELL; MOUSE; MULTIMODALITY CANCER THERAPY; NONHUMAN; PERITUMORAL INJECTION; SUBCUTANEOUS TISSUE TUMOR; TUMOR VOLUME;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, CD86; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL DIFFERENTIATION; CELL GROWTH PROCESSES; COMBINED MODALITY THERAPY; DENDRITIC CELLS; FEMALE; HUMANS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; OLIGODEOXYRIBONUCLEOTIDES; RADIOTHERAPY;

MUS;

EID: 70349973834     PISSN: 17534259     EISSN: 17534267     Source Type: Journal    
DOI: 10.1177/1753425909105581     Document Type: Article

References (30)

1. Furumoto K., Soares L., Engleman EG, Merad M. Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. J Clin Invest 2004; 113: 774-783.
2. Bui JD, Schreiber RD Cancer immunosurveillance, immunoediting and inflammation: Independent or interdependent processes? Curr Opin Immunol 2007; 19: 203-208.
3. Pinzon-Charry A., Maxwell T., Lopez JA Dendritic cell dysfunction in cancer: A mechanism for immunosuppression. Immunol Cell Biol 2005; 83: 451-461.
4. Novakovic S., Stegel V., Kopitar A., Ihan A., Novakovic BJ Preventive and therapeutic effect of tumor vaccine composed of CpG ODN class C and irradiated tumor cells is triggered through the APCs and activation of CTLs. Vaccine 2007; 25: 8241-8256.
5. Malmberg KJ, Ljunggren HG Escape from immune- and nonimmune-mediated tumor surveillance. Semin Cancer Biol 2006; 16: 16-31.
6. Krieg AM Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006; 5: 471-484.
7. Davila E., Celis E. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity. J Immunol 2000; 165: 539-547.
8. Jahrsdorfer B., Weiner GJ CpG oligodeoxynucletides as immunotherapy in cancer. Update Cancer Ther 2008; 3: 27-32.
9. Brown L., Roda BS, Terrell C. et al. Interferon α and CpG oligodeoxynucleotides elicit additive immunostimulatory and antitumor effects. Surgery 2006; 140: 297-306.
10. Kaisho T., Akira S. Toll-like receptor function and signaling. J Allergy Clin Immunol 2006; 117: 979-987.
11. Pilon-Thomas S., Li W., Briggs JJ, Djeu J., Mule JJ, Riker AI Immunostimulatory effects of CpG-ODN upon dendritic cell-based immunotherapy in murine melanoma model. J Immunother 2006; 29: 381-387.
12. Friedberg JW, Kim H., McCauley M. et al. Combination immunotherapy with CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: Increased interferon-α/β-inducible gene expression, without significant toxicity. Blood 2005; 105: 489-495.
13. Weeratna RD, Davis HL, Medynski L., Krieg AM Potential use of CpG ODN for cancer immunotherapy. Update Cancer Ther 2006; 1: 49-58.
14. Stegel V., Kopitar A., Jezersek NB, Ihan A., Novakovic S. Dendritic cells incubated with irradiated tumor cells effectively stimulate T lymphocyte activation and induce enhanced expression of CD69, CD25 as well as production of IFNβ and IL4. Int Immunopharmacol 2006; 6: 79-89.
15. den Brok Mhmgm, Sutmuller RPM, Nierkens S. et al. Synergy between in situ cryoablation and TLR9 stimulation results in a highly effective in vivo dendritic cell vaccine. Cancer Res 2006; 66: 7285-7292.
16. Lonsdorf AS, Kuekrek H., Stern BV, Boehm BO, Lehmann PV, Tary-Lehmann M. Intratumor CpG-oligodeoxynucletide injection induces protective antitumor T cell immunity. J Immunol 2003; 171: 3941-3946.
17. Heckelsmiller K., Beck S., Rall K. et al. Combined dendritic cell-and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy. Eur J Immunol 2002; 32: 3235-3245.
18. Switaj T., Jalili A., Jakubowska AB et al. CpG immunostimulatory oligodeoxynucletide 1826 enhances antitumor effect of interleukin 12 gene-modified tumor vaccine in a melanoma model in mice. Clin Cancer Res 2004; 10: 4165-4175.
19. Mason KA, Neal R., Hunter N., Ariga H., Ang K., Milas L. CpG oligodeoxynucleotides are potent enhancers of radio- and chemoresponses of murine tumors. Radiother Oncol 2006; 80: 192-198.
20. Mason KA, Ariga H., Neal R. et al. Targeting Toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy. Clin Cancer Res 2005; 11: 361-369.
21. Milas L., Mason KA, Ariga H. et al. CpG oligodeoxynucleotides enhances tumor response to radiation. Cancer Res 2004; 64: 5074-5077.
22. Meng Y., Carpentier AF, Chen L. et al. Successful combination of local CpG ODN and radiotherapy in malignant glioma. Int J Cancer 2005; 116: 992-997.
23. + T cell responses to vaccination with peptide, IFA and CpG oligodeoxynucletide 7909. J Clin Invest 2005; 115: 739-746.
24. Saha A., Baral RN, Chatterjee SK et al. CpG oligonucleotides enhance the tumor antigen-specific immune response of an antiidiotype antibody-based vaccine strategy in CEA transgenic mice. Cancer Immunol Immunother 2006; 55: 515-527.
25. Carpentier A., Laigle-Donadey F., Zohar S. et al. Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. Neurol Oncol 2006; 8: 60-66.
26. Ohashi K., Kobayashi G., Fang S. et al. Surgical excision combined with autologous whole tumor cell vaccination is an effective therapy for murine neuroblastoma. J Pediatr Surg 2006; 41: 1361-1368.
27. Spector SA, Tyndall M., Kelley E. Effects of acyclovir combined with other antiviral agents on human cytomegalovirus. Am J Med 1982; 73: 36-39.
28. Merad M., Sugie T., Engleman EG, Fong L. In vivo manipulation of dendritic cells to induce therapeutic immunity. Blood 2002; 99: 1676-1682.
29. Buhtoiarov IN, Sondel PM, Eickhoff JC, Rakhmilevich AL Macrophages are essential for antitumour effects against weakly immunogenic murine tumours induced by class B CpG-oligodeoxynucleotides. Immunology 2006; 120: 412-423.
30. Zhu B., Zou L., Cheng X. et al. Administration of MIP-3α gene to the tumor following radiation therapy boosts anti-tumor immunity in a murine model of lung carcinoma. Immunol Lett 2006; 103: 101-107.